Skip to main content
main-content

Zeitschrift

Investigational New Drugs

Investigational New Drugs 1/2013

Ausgabe 1/2013

Inhaltsverzeichnis ( 27 Artikel )

01.02.2013 | PRECLINICAL STUDIES | Ausgabe 1/2013

Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent

Sang Joon Shin, Jee Won Hwang, Joong Bae Ahn, Sun Young Rha, Jae Kyung Roh, Hyun Cheol Chung

01.02.2013 | PRECLINICAL STUDIES | Ausgabe 1/2013

A preclinical and clinical study of mycophenolate mofetil in pancreatic cancer

J. Rodríguez-Pascual, P. Sha, E. García-García, N. V. Rajeshkumar, E. De Vicente, Y. Quijano, A. Cubillo, B. Angulo, O. Hernando, M. Hidalgo

01.02.2013 | PRECLINICAL STUDIES | Ausgabe 1/2013

Inhibitors of cathepsins B and L induce autophagy and cell death in neuroblastoma cells

Donna M. Cartledge, Rita Colella, Lisa Glazewski, Guizhen Lu, Robert W. Mason

01.02.2013 | PRECLINICAL STUDIES | Ausgabe 1/2013

Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines

Brigette B. Y. Ma, Vivian W. Y. Lui, Crystal S. Cheung, Cecilia P. Y. Lau, Kakiu Ho, Edwin P. Hui, Stephen K. W. Tsui, Margaret H. Ng, S. H. Cheng, Patrick K. S. Ng, Sai Wai Tsao, Anthony T. C. Chan

01.02.2013 | PRECLINICAL STUDIES | Ausgabe 1/2013

Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines

Jodi A. Muscal, Kathleen A. Scorsone, Linna Zhang, Jeffrey A. Ecsedy, Stacey L. Berg

01.02.2013 | PRECLINICAL STUDIES | Ausgabe 1/2013

Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer

Nilesh A. Patankar, Dawn Waterhouse, Dita Strutt, Malathi Anantha, Marcel B. Bally

01.02.2013 | PRECLINICAL STUDIES | Ausgabe 1/2013

Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study

Anne Sudaka, Antoine Susini, Cristiana Lo Nigro, Jean-Louis Fischel, Nicolas Toussan, Patricia Formento, Federica Tonissi, Laura Lattanzio, Elvio Russi, Marie-Christine Etienne-Grimaldi, Marco Merlano, Gérard Milano

01.02.2013 | PRECLINICAL STUDIES | Ausgabe 1/2013

Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinases

Teresa G. Granda, David Cebrián, Sonia Martínez, Patricia Villanueva Anguita, Estela Casas López, Wolfgang Link, Teresa Merino, Joaquín Pastor, Beatriz G. Serelde, Sandra Peregrina, Irene Palacios, Maria Isabel Albarran, Antonio Cebriá, Milagros Lorenzo, Patricia Alonso, Jesús Fominaya, Ana Rodríguez López, James R. Bischoff

01.02.2013 | PHASE I STUDIES | Ausgabe 1/2013 Open Access

Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors

Christina M. Annunziata, Elise C. Kohn, Patricia LoRusso, Nicole D. Houston, Robert L. Coleman, Manuela Buzoianu, Gabriel Robbie, Robert Lechleider

01.02.2013 | PHASE I STUDIES | Ausgabe 1/2013 Open Access

A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer

Sil Kordes, Dick J. Richel, Heinz-Josef Klümpen, Mariëtte J. Weterman, Arnoldus J. W. M. Stevens, Johanna W. Wilmink

01.02.2013 | PHASE I STUDIES | Ausgabe 1/2013

Phase I trial of dasatinib and ixabepilone in patients with solid tumors

P. Herbolsheimer, R. Kapoor, K. L. Smith, D. Perry, N. Verma, I. Veytsman, J. Jelinek, S. M. Swain

01.02.2013 | PHASE I STUDIES | Ausgabe 1/2013 Open Access

A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma

Thomas Yau, P. N. Cheng, Pierre Chan, William Chan, Li Chen, Jimmy Yuen, Roberta Pang, S. T. Fan, Ronnie T. Poon

01.02.2013 | PHASE I STUDIES | Ausgabe 1/2013

First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours

Yasuhito Fujisaka, Yusuke Onozawa, Takayasu Kurata, Hirofumi Yasui, Isao Goto, Kentaro Yamazaki, Nozomu Machida, Junichiro Watanabe, Hitoshi Shimada, Xiaojin Shi, Narikazu Boku

01.02.2013 | PHASE I STUDIES | Ausgabe 1/2013

A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer

A. Dasari, L. Gore, W. A. Messersmith, S. Diab, A. Jimeno, C. D. Weekes, K. D. Lewis, H. A. Drabkin, T. W. Flaig, D. R. Camidge

01.02.2013 | PHASE I STUDIES | Ausgabe 1/2013

Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent

Matthew Burge, Alessandra B. Francesconi, Dusan Kotasek, Rosa Fida, Gregg Smith, Andrew Wilks, Paul A. Vasey, Jason D. Lickliter

01.02.2013 | PHASE I STUDIES | Ausgabe 1/2013

Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer

Glen J. Weiss, Ross C. Donehower, Tara Iyengar, Ramesh K. Ramanathan, Karen Lewandowski, Eric Westin, Karla Hurt, Scott M. Hynes, Stephen P. Anthony, Scott McKane

01.02.2013 | PHASE II STUDIES | Ausgabe 1/2013

A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma

Christopher W. Ryan, Chacon Matias, Mark Agulnik, Antonio Lopez-Pousa, Charles Williams, Dinesh P. de Alwis, Christopher Kaiser, Mary Alice Miller, Sabine Ermisch, Robert Ilaria Jr, M. L. Keohan

01.02.2013 | PHASE II STUDIES | Ausgabe 1/2013

Phase II study of irinotecan plus capecitabine in anthracycline- and taxane- pretreated patients with metastatic breast cancer

Keun Seok Lee, In Hae Park, Byung-Ho Nam, Jungsil Ro

01.02.2013 | PHASE II STUDIES | Ausgabe 1/2013

Investigation of bendamustine HCL in a Phase 2 study in women with resistant ovarian cancer

Amanda F. Baker, Denise J. Roe, Cynthia Laughren, Janice L. Cohen, Heather M. Wright, Mary C. Clouser, Haiyan Cui, David S. Alberts, Setsuko K. Chambers

01.02.2013 | PHASE II STUDIES | Ausgabe 1/2013

Pemetrexed in patients with refractory soft tissue sarcoma: A non-comparative multicenter phase II study of the German Sarcoma Group AIO-STS 005

J. T. Hartmann, S. Bauer, G. Egerer, M. S. Horger, H.-G. Kopp, V. Grünwald, F. Mayer

01.02.2013 | PHASE II STUDIES | Ausgabe 1/2013 Open Access

Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer

Christian Manegold, Johan Vansteenkiste, Felipe Cardenal, Wolfgang Schuette, Penella J. Woll, Ernst Ulsperger, Anne Kerber, Josef Eckmayr, Joachim von Pawel

01.02.2013 | PHASE II STUDIES | Ausgabe 1/2013

Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy

Yong Sang Hong, Jeeyun Lee, Kyu-pyo Kim, Jae-Lyun Lee, Young Suk Park, Joon Oh Park, Se Hoon Park, Sun Young Kim, Ji Yeon Baek, Jee Hyun Kim, Keun-Wook Lee, Tae-You Kim, Tae Won Kim

01.02.2013 | SHORT REPORT | Ausgabe 1/2013

The PDT activity of free and pegylated pheophorbide a against an amelanotic melanoma transplanted in C57/BL6 mice

Valentina Rapozzi, Sonia Zorzet, Marina Zacchigna, Sara Drioli, Luigi E. Xodo

01.02.2013 | SHORT REPORT | Ausgabe 1/2013

RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications

Antonio Garcia-Gomez, Enrique M. Ocio, Atanasio Pandiella, Jesús F. San Miguel, Mercedes Garayoa

01.02.2013 | SHORT REPORT | Ausgabe 1/2013

Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel

Alexander N. Wein, Shihui Liu, Yi Zhang, Andrew T. McKenzie, Stephen H. Leppla

01.02.2013 | REVIEW | Ausgabe 1/2013

Investigational agents in development for the treatment of ovarian cancer

Shannon N. Westin, Thomas J. Herzog, Robert L. Coleman

01.02.2013 | REVIEW | Ausgabe 1/2013

Development of artemisinin compounds for cancer treatment

Henry C. Lai, Narendra P. Singh, Tomikazu Sasaki

Aktuelle Ausgaben

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise